eli lilly sues compounders for selling unauthorized tirzepatide copies finds impurity in compounded version of its weight-loss drug, warns of health risks FDA's Weight Loss Drug 'No

Peptide therapy has changed the lives of many people across the globe

Published this week in The Lancet Diabetes & Endocrinology , the research findings looked at 11 large-scale trials investigating seven medications in the GLP-1 receptor agonist class, including semaglutide (sold as Ozempic or Wegovy), dulaglutide (sold as Trulicity), and liraglutide (sold as Victoza)

References View all references + Sikiri, P., et al

Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials

RAAS, reninangiotensinaldosterone system